Noveome Biotherapeutics Growth, Revenue, Number of Employees and Funding
Estimated Revenue & Financials
- Noveome Biotherapeutics's estimated revenue is currently $5.4M per year.
- Noveome Biotherapeutics's estimated revenue per employee is $146622
- Noveome Biotherapeutics has 37 Employees.
- Noveome Biotherapeutics grew their employee count by 6% last year.
- Noveome Biotherapeutics currently has 1 job openings.
|Chad Glyde||Director Of Quality|
|RANDALL RUPP||EVP Manufacturing & Development|
|LARRY BROWN||EVP R&D/Chief Scientific Officer|
|Rick Banas||Director of Cell Therapy and Research at Noveome Biotherapeutics, Inc.|
|Stephen Raat||Associate Director of QA|
|Cathy Trumpower||Associate Director of Manufacturing|
|Howard Wessel||Associate Director of Research and Development|
|Tammy McCracken||Vice President, Regulatory Affairs and Quality|
|David STEED||EVP medical Affairs/Chief Medical Officer|
|Marianne Cascino||Director Project Management|
What Is Noveome Biotherapeutics?
Noveome Biotherapeutics, Inc. is a clinical stage company focused on breakthrough therapies for the regenerative repair of inflamed or damaged tissues. The company, originally founded as Stemnion, Inc., is located in the heart of Pittsburgh near the Southside Works. Noveome is passionate about growing its business in Allegheny County and helping the region to become a world leader in biotherapeutic research and development. Noveome Biotherapeutics, Inc. is a dynamic biopharmaceutical company with an innovative platform technology that represents a paradigm shift in drug development. Unlike most drugs that are single molecules directed at specific indications, Noveome?s product is a complex mixture of biomolecules that is believed to have the ability to treat a wide range of conditions and injuries. Noveome collaborates with major research centers to advance these therapeutic applications.keywords:N/A
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Noveome Biotherapeutics News
PITTSBURGH--(BUSINESS WIRE)-- Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing ...
CORRECTING and REPLACING Noveome Biotherapeutics, Inc. Announces the First Patient Dosed in Phase 2 Open Label Clinical Trial ...
PITTSBURGH--(BUSINESS WIRE)--Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing ...